Upstream Bio (NASDAQ:UPB) Posts Earnings Results, Beats Expectations By $0.05 EPS

Upstream Bio (NASDAQ:UPB) announced its quarterly earnings data on Tuesday. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.05, FiscalAI reports. The company had revenue of $0.77 million during the quarter, compared to analysts’ expectations of $0.43 million. Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%.

Upstream Bio Stock Performance

Upstream Bio stock opened at $7.42 on Tuesday. Upstream Bio has a fifty-two week low of $5.85 and a fifty-two week high of $33.68. The stock’s 50 day simple moving average is $6.83 and its two-hundred day simple moving average is $10.43. The stock has a market cap of $403.74 million, a price-to-earnings ratio of -2.54 and a beta of 1.26.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in UPB. Vanguard Group Inc. boosted its position in shares of Upstream Bio by 12.5% during the third quarter. Vanguard Group Inc. now owns 2,442,551 shares of the company’s stock valued at $45,944,000 after purchasing an additional 271,718 shares in the last quarter. Janus Henderson Group PLC purchased a new position in Upstream Bio during the fourth quarter valued at $41,423,000. State Street Corp lifted its position in Upstream Bio by 18.4% during the fourth quarter. State Street Corp now owns 1,319,226 shares of the company’s stock valued at $35,817,000 after buying an additional 204,645 shares during the period. Marshall Wace LLP boosted its holdings in shares of Upstream Bio by 198.8% during the 3rd quarter. Marshall Wace LLP now owns 867,999 shares of the company’s stock valued at $16,327,000 after buying an additional 577,473 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Upstream Bio by 4.3% during the 4th quarter. Geode Capital Management LLC now owns 851,908 shares of the company’s stock valued at $23,134,000 after buying an additional 34,799 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on UPB shares. JPMorgan Chase & Co. lowered Upstream Bio from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $35.00 to $8.00 in a research note on Friday, June 12th. HC Wainwright initiated coverage on shares of Upstream Bio in a report on Wednesday, June 3rd. They set a “buy” rating and a $36.00 price target for the company. Mizuho lowered their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Upstream Bio in a research report on Monday, August 3rd. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Upstream Bio has an average rating of “Hold” and an average target price of $33.17.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.